Search alternatives:
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ns decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
461
-
462
-
463
-
464
-
465
-
466
-
467
-
468
-
469
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
470
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
471
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
472
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
473
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
474
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer’s Disease
Published 2022“…<b>SZM679</b>, a highly specific RIPK1 inhibitor (<i>K</i><sub>d,RIPK1</sub> = 8.6 nM, <i>K</i><sub>d,RIPK3</sub> > 5000 nM), was developed by our group with superior high antinecroptotic activity (EC<sub>50</sub> = 2 nM), and investigated to completely reverse the tumor necrosis factor-induced systemic inflammatory response syndrome. …”
-
475
-
476
-
477
-
478
-
479
HDM exposure results in increased MIP-2 and decreased IFNα and IL-13.
Published 2014“…<p>Adult female BALB/c mice were exposed to 25 μg of HDM protein (or control) daily for 10 days. On day 9 they were infected with 1×10<sup>8</sup> TCID<sub>50</sub> HRV-1B or inactivated virus. …”
-
480